PELP-1 promotes adverse endocrine therapy response in ER plus breast cancer

被引：0
|
作者：
Rees, Michael [1 ]
Smith, Chris [2 ]
Barrett-Lee, Peter [1 ]
Hiscox, Stephen [2 ]
机构：
[1] Velindre Canc Ctr, Cardiff, S Glam, Wales
[2] Cardiff Univ, Cardiff, S Glam, Wales
来源：
CANCER RESEARCH | 2018年 / 78卷 / 13期
关键词：
D O I：
10.1158/1538-7445.AM2018-2884
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2884
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Breast Cancer: Palbociclib plus endocrine Therapy versus Capecitabine
    Lorenz, Judith
    GEBURTSHILFE UND FRAUENHEILKUNDE, 2021, 81 (06)
  • [42] Endocrine Therapy plus Zoledronic Acid in Premenopausal Breast Cancer
    Berruti, Alfredo
    Buttigliero, Consuelo
    Dogliotti, Luigi
    NEW ENGLAND JOURNAL OF MEDICINE, 2009, 360 (22): : 2368 - 2368
  • [43] Endocrine Therapy plus Zoledronic Acid in Premenopausal Breast Cancer
    Gnant, Michael
    Mlineritsch, Brigitte
    Schippinger, Walter
    Luschin-Ebengreuth, Gero
    Poestlberger, Sabine
    Menzel, Christian
    Jakesz, Raimund
    Seifert, Michael
    Hubalek, Michael
    Bjelic-Radisic, Vesna
    Samonigg, Hellmut
    Tausch, Christoph
    Eidtmann, Holger
    Steger, Guenther
    Kwasny, Werner
    Dubsky, Peter
    Fridrik, Michael
    Fitzal, Florian
    Stierer, Michael
    Rucklinger, Ernst
    Greil, Richard
    NEW ENGLAND JOURNAL OF MEDICINE, 2009, 360 (07): : 679 - 691
  • [44] Ribociclib plus Endocrine Therapy in Early Breast Cancer REPLY
    Slamon, Dennis
    Yardley, Denise A.
    Hortobagyi, Gabriel
    NEW ENGLAND JOURNAL OF MEDICINE, 2024, 390 (23): : 2221 - 2222
  • [45] Overall Survival with Ribociclib plus Endocrine Therapy in Breast Cancer
    Im, S. -A.
    Lu, Y. -S.
    Bardia, A.
    Harbeck, N.
    Colleoni, M.
    Franke, F.
    Chow, L.
    Sohn, J.
    Lee, K. -S.
    Campos-Gomez, S.
    Villanueva-Vazquez, R.
    Jung, K. -H.
    Chakravartty, A.
    Hughes, G.
    Gounaris, I.
    Rodriguez-Lorenc, K.
    Taran, T.
    Hurvitz, S.
    Tripathy, D.
    NEW ENGLAND JOURNAL OF MEDICINE, 2019, 381 (04): : 307 - 316
  • [46] IncRNA-protein interactions that predict response to endocrine therapy in HR plus breast cancer
    Waiters, Kacie D.
    Quttina, Maram
    Khan, Ashfia F.
    Karami, Samaneh
    Peidl, Anthony
    Babajide, Funmi
    Bawa-Khalfe, Tasneem
    CANCER RESEARCH, 2024, 84 (03)
  • [47] lncRNA-protein interactions that predict response to endocrine therapy in HR plus breast cancer
    Waiters, Kacie D.
    Quttina, Maram
    Khan, Ashfia F.
    Karami, Samaneh
    Peidl, Anthony S.
    Babajide, Funmi
    Bawa-Khalfe, Tasneem
    CANCER RESEARCH, 2024, 84 (06)
  • [48] Enhancing response to estrogen therapy in ER plus breast cancer with novel scheduling and dosing regimens
    Traphagen, N. A.
    Hosford, S. R.
    Miller, T. W.
    CANCER RESEARCH, 2019, 79 (04)
  • [49] Endocrine therapy resistance in estrogen receptor (ER)-positive breast cancer
    De Marchi, Tommaso
    Foekens, John A.
    Umar, Arzu
    Martens, John W. M.
    DRUG DISCOVERY TODAY, 2016, 21 (07) : 1181 - 1188
  • [50] The CGA gene as new predictor of the response to endocrine therapy in ERα-positive postmenopausal breast cancer patients
    Bièche, I
    Parfait, B
    Noguès, C
    Andrieu, C
    Vidaud, D
    Spyratos, F
    Lidereau, R
    Vidaud, M
    ONCOGENE, 2001, 20 (47) : 6955 - 6959
12345